Loading...

Advanced Automation And Personalized Medicine Will Shape Healthcare's Future

Published
16 Mar 25
Updated
04 Oct 25
AnalystConsensusTarget's Fair Value
CHF 215.73
31.1% undervalued intrinsic discount
04 Oct
CHF 148.70
Loading
1Y
-43.8%
7D
-3.6%

Author's Valuation

CHF 215.7331.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on04 Oct 25
Fair value Decreased 2.15%

Analysts have adjusted their price target for Tecan Group downward, reducing the fair value estimate from CHF 220.47 to CHF 215.73. This change is due to a slight increase in the discount rate, although forecasts for revenue growth and profit margins have improved.

Shared on05 Sep 25

Analysts have lowered their outlook for Tecan Group due to concerns over near-term margin pressure, cautious end-market demand, and delayed recovery in key segments, though the consensus price target remained unchanged at CHF220.47. Analyst Commentary Cautious sentiment due to anticipation of "soft" first-half financial results impacting near-term performance.

Shared on01 May 25
Fair value Decreased 7.95%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 0.083%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 6.53%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.